BACKGROUND
Occupational health nurses have long been proponents of preventive health . They have introduced effective wellness programs in the workplace which have positively impacted the health of American workers. Coronary heart disease (CHD) will cause the death of many Americ ans if appropriate intervention s are not made. Occupational health nurses are being challenged to educate all employees, provide CHD risk assessment, conduct screenings, make necessary referrals, and implement ongoing wellness and intervention programs so employee s may attain and retain their optimum level of heart health.
Evidence showing the cardioprotective effect of controlling hypercholesterolemia has emerged in the literature since the early 1990s (Aronow, 200 I; Assmann, 1992; Herbert, 1997; Rubins, 1999; Ryan, 1999 ). An
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undisputed key step in reducing CHD risk is lowering blood cholesterol levels. The National Cholesterol Education Program (NCEP) has provided guidelines on how adults can lower cholesterol levels (Expert Panel on Detection, Evaluation, and Treatment of High Blood Chole sterol in Adults, 2001) . Their recently published third report, the Adult Treatment Panel III (ATPIII), broaden s the indication s for cholesterol lowering therapy.
The proper implementation of these new guidelines is expected to significantly increase the number of individuals, including workers, who need treatment for hyperchole sterolemia both pharmacologically and nonpharmacol ogically. The new guidelines emphasize the importance of more accurate identification of individuals who have a high risk of a CHD event and matching the aggressiveness of treatment to each person 's level of risk.
ADULT TREATMENT PANEL III RECOMMENDATIONS
In this article, ATPIII recommendations are addressed and suggestions are offered on how occupational health nurses can use them in their practice. It is important for the occupational health nurse to: • Assess the lipid profile . • Assess the CHD risk.
• Refer for appropriate treatment.
• Educate about therapeutic lifestyle changes.
• Reinforce or educate about the importance of medication compliance.
Assess the Lipid Profile
When implementing a program to identify employees at risk, every adult older than age 20 should have a 12 hour fasting lipid profile. Individuals with normal find- ings should have this test repeated every 5 years. A full lipid profile includes both a total cholesterol screen and subcomponents used in the evaluation of the employee and for planning appropriate intervention. The most important measure in the profile is the low density lipoprotein cholesterol (LDL-C). An elevated LDL-C is a major cause of CHD; the higher the LDL-C, the greater the risk (see Table I ).
The high density lipoprotein cholesterol (HDL-C), known as the "good" cholesterol, is inversely associated with CHD risk: the lower the HDL-C, the greater the risk. An HDL-C level of 60 mg/dL or greater is classified as high and is related to a lower CHD risk.
The ATPIII emphasizes the importance of triglycerides in assessing CHD risk. Table 2 summarizes the classification levels for triglycerides. The ATPIII suggests an elevated triglyceride level, greater than 150 mg/dL, is a CHD risk predictor. Elevated triglycerides indicate the presence of very low density lipoproteins (VLDL). It is the VLDL particles that contribute to elevated risk, not the triglycerides (Hokanson, 1996) .
Assess Coronary Heart Disease Risk
Once the fasting lipid profile has been ascertained and evaluated, the occupational health nurse should obtain a history of clinical CHD events and risk factors.
Employees who have experienced a CHD event have a 20% or greater risk of experiencing another event over a 10 year period. The occupational health nurse can identify a employee with CHD by assessing the presence of one or more of the following: • History of an myocardial infarction (MI). • Evidence of a silent MI or myocardial ischemia. • History of unstable angina. • Signs and symptoms of stable angina pectoris.
• Revascularization procedures such as coronary bypass surgery and angioplasty.
The ATPIII guidelines also include individuals in this high risk category who have not yet experienced a CHD event, but have CHD risk equivalent factors. These individuals may fall into one of the following three groups (Grundy, 1997 • Employees diagnosed with adult onset diabetes (TypeIT).
• Individuals with two or more of the listed coronary risk factors in Table 3 . For employees with two or more CHD risk factors, ATPIII included a further assessment tool to determine their risk for developing CHD within 10 years. This tool, the Framingham Risk Scoring Method, estimates the 10 year CHD risk in these individuals enabling identification of persons who would benefit from more intensive treatment. Risk factors used in this method include age, total cholesterol, HDL-C, blood pressure status, and cigarette smoking. Based on the sum of points for each risk factor, individuals are categorized as having a 10 year risk for CHD of greater than 20%, 10% to 20%, or less than 10% (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001). 
Refer for Appropriate Treatment
The occupational health nurse understands that the basic principle of cholesterol management is the intensity of therapy should match the level of CHD risk. After the occupational health nurse assesses the employee, referral to the employee's primary care provider may be necessary to ensure the employee receives an appropriate and effective treatment modality.
Educate About the Importance of Therapeutic Lifestyle Changes and Medication Compliance
The primary treatment goal for employees with established CHD or CHD risk equivalent is to achieve a LDL-C level of less than 100 mg/dL. Regardless of an individual's LDL-C level, lifestyle modifications should be initiated. For CHD or CHD risk equivalent employees with a LDL-C of 130 mg/dL or greater, drug therapy and lifestyle modification are suggested.
For CHD or CHD risk equivalent employees with an LDL-C of between 100mg/dL and 129 mg/dL, several options are available. A 3 month lifestyle change trial period may be initiated. If the LDL-C level does not decrease, drug therapy is recommended. For CHD or CHD risk equivalent employees with a LDL-C of less than 100 mg/dL, lifestyle modification is indicated. The presence of CHD in these individuals suggests the LDL-C level is too high, whatever the level.
The goal of treatment for employees with at least two risk factors and a 10 year risk of greater than 20% is to obtain LDL-C levels below 130 mg/dL. Lifestyle changes are recommended first. If the goal of less than 130 mg/dL is not achieved, drug therapy is indicated.
Drug therapy is considered for employees with two or more risk factors and a 10 year CHD risk between 10% and 20% if the LDL-C goal of less than 130 mg/dL is not 362 achieved with lifestyle changes in 3 months. If the 10 year CHD risk factor is less than 10%, emphasis is placed on reducing long term risk with lifestyle modifications. Table 4 defines LDL-C goals and recommended levels for lifestyle changes and drug therapy according to risk category.
THERAPEUTIC LIFESTYLE CHANGES
Risk reduction for CHD begins with the adoption of a healthy lifestyle. The occupational health nurse is an educator and can effectively teach employees about the ATPIII recommended plan to achieve LDL-C goals. In most individuals, this method is tried before initiating drug therapy. In high risk employees, drug therapy may be given simultaneously with therapeutic lifestyle changes. Components of therapeutic lifestyle changes include: • Reduced intake of LDL raising nutrients. Saturated fats « 7% of total calories) and dietary cholesterol « 200 mg/day). 
DRUG THERAPY
The goal of drug therapy is to lower the LDL-C to goal level. The occupational health nurse can educate cholesterol levels of less than 100 mg/dL as optimal for all clients.
2 The ATPIII focuses on lowering lowdensity lipoprotein cholesterol as a primary initiative and using exercise, diet, and pharmacotherapy as a means for lowering coronary heart disease and risks. 4 The ATPIII places increased attention on high triglyceride levels (> 200 mg/dL) and on early detection and appropriate aggressive treatment for clients at risk for coronary heart disease and events.
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Statins are the preferred choice because they are highly effective in lowering LDL-C and are generally considered safe. Statins inhibit the biosynthesis of cholesterol by blocking the enzyme 3HMG-CoA reductase. This enzyme is necessary for the body to manufacture cholesterol. Five statins are currently available: • Atorvastin (Lipitor). • Fluvastatin (Lescol). • Lovastatin (Mevacor). • Pravastatin (Pravachol). • Zimvastatin (Zocor).
Statins may increase transaminase enzymes, suggesting hepatotoxicity, and may cause myopathy. Fortunately, liver enzyme changes occur in less than 1% of individuals and quickly return to normal when the statin is withdrawn.
Bile acid sequestrants or resins (BARs) also lower LDL-C levels. They bind bile acids and lipids so the body does not absorb them, but passes them through the gastrointestinal tract where they are eliminated. Bile acid sequestrants or resins have been shown to reduce CHD events. Often they are administered with a statin where their effect is additive. Cholestyramine (Questran), colestipol (Colestid), and cholesevelam (WeIchol) are currently available.
Niacin (nicotinic acid) lowers LDL-C and triglyceride levels. It is the most effective drug available for raising HDL-C. The major limitation to niacin is its side effects including flushing and liver toxicity, which can occur when taking sustained release niacin in doses above 2 grams daily.
Fibrates (Tricor and Lopid) reduce the production of triglycerides and raise HDL-C levels. Fibrates may cause myopathy when used in combination with a statin.
The new ATPIII guidelines identify more individuals who qualify for aggressive treatment to obtain an LDL-C below 100mg/dL. This means combination therapy may be used more often. Lowering LDL-C can be enhanced by combining two or more LDL-C lowering medications (e.g., statin with a BAR; statin with niacin; statin, BAR, niacin combination). Adding a BAR or niacin to a low dose statin achieves the same effect as quadrupling the statin dose.
On July 24, 2001, the American Heart Association issued an advisory recommending against prescribing hormone replacement therapy (HRT) for primary or secondary prevention of CHD in women older than age 50 (American Heart Association, 2001). The recommendation is based on review of clinical investigations that indicate a possible harmful effect associated with HRT use in women with CHD. Pending the results of ongoing studies, the guidelines recommend the decision to use HRT be based on nonheart related risks and benefits.
CONCLUSION
The NCEP/ATPIII guidelines have the potential to assist millions of individuals to avoid CHD events. However, these lifesaving guidelines must be implemented
